Asset Details
Do you wish to reserve the book?
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
Do you wish to request the book?
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
2021
Overview
In a trial comparing the JAK inhibitor upadacitinib (15 or 30 mg daily) with placebo and with the TNF-α inhibitor adalimumab, the percentage of patients with an ACR20 response at 12 weeks was 70.6% with the 15-mg dose, 78.5% with the 30-mg dose, 36.2% with placebo, and 65.0% with adalimumab. There were hepatic disorders with upadacitinib.
Publisher
Massachusetts Medical Society
Subject
/ Adalimumab - therapeutic use
/ Adult
/ Antirheumatic Agents - administration & dosage
/ Antirheumatic Agents - adverse effects
/ Antirheumatic Agents - therapeutic use
/ Arthritis, Psoriatic - drug therapy
/ Dosage
/ Dose-Response Relationship, Drug
/ Female
/ Heterocyclic Compounds, 3-Ring - administration & dosage
/ Heterocyclic Compounds, 3-Ring - adverse effects
/ Heterocyclic Compounds, 3-Ring - therapeutic use
/ Humans
/ Janus Kinase Inhibitors - therapeutic use
/ Male
/ Pain
/ Patients
/ Placebos
